Nuria Ribelles

Università degli Studi del Piemonte Orientale “Amedeo Avogadro” — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index4.7kcitations171works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(71), HER2/EGFR in Cancer Research(54), Cancer Treatment and Pharmacology(44), Advanced Breast Cancer Therapies(36), Cancer Genomics and Diagnostics(15)

Publications169 total

Abstract PS3-01-27: Association between adherence to the mediterranean dietary pattern and PAM50-derived breast cancer proliferation and recurrence risk scores. Exploratory analysis from the Epigeicam study
Clinical Cancer Research·2026
Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
UNC Libraries·2026Open Access
Figure 2 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Figure 5 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Figure 3 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Table 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Figure 4 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Data from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Supplementary Data 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer
2026Open Access
Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Clinical Cancer Research·2026Open Access
Case Report: Personalized management of HER2-positive breast cancer with advanced nodal disease during pregnancy: a clinical case and review
Frontiers in Oncology·2026Open Access
Oncology data extraction with large language models from real-world breast cancer electronic health records in Spanish
Machine Learning with Applications·2026Open Access
Associations of the HER2DX Genomic Test with Biological and Pathological Features in HER2-positive Breast Cancer.
Open MIND·2026
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy
Frontiers in Oncology·2025Open Access
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)
Clinical & Translational Oncology·2025Open Access
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
Breast Cancer Research·2025· 1 citedOpen Access
OS-033 Liver injury induced by CDK4/6 inhibitors for metastatic breast cancer: characterization and management. Data from a multicenter study
Journal of Hepatology·2025
Oncology Data Extraction with Large Language Models from Real-World Electronic Health Records in Spanish
SSRN Electronic Journal·2025Open Access
Named entity recognition for de-identifying Spanish electronic health records
Computers in Biology and Medicine·2024· 3 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Emilio Alba(33), Lourdes Calvo(12), Alfonso Sánchez‐Muñoz(12), Miguel Martín(11), Begoña Jiménez(10), José M. Jerez(9), Eva Carrasco(9), Antonia Márquez(9), Aleix Prat(8), Aňa Lluch(8), Bella Pajares(7), Agustí Barnadas(7), Pedro Sánchez‐Rovira(7), Leonardo Franco(6), Antonio Llombart‐Cussac(6), José Ignacio Chacón(6), Arrate Plazaola(6), Mireia Margelí Vila(6), Amparo Ruı́z(5), Miguel Ángel Seguí(5)